Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/06/微信截图_20240618112716.jpg)
Pioneering Chinese Medical Team: Intranasal Neural Stem Cell Transplantation for Parkinson’s Disease, Clinical Trial a Great Success!
**Pioneering Chinese Medical Team: Intranasal Neural Stem Cell Transplantation for Parkinson’s Disease, Clinical Trial a Great Success!**
![Parkinson's Disease](https://www.medtourcn.com/wp-content/uploads/2024/06/微信截图_20240618112716.jpg)
Parkinson’s Disease
**Breakthrough Research**
The expert team at Peking Union Medical College Hospital (PUMCH) has conducted the world’s first clinical trial (ANGE-S003) using intranasal human neural stem cell transplantation to treat Parkinson’s disease, yielding promising results and offering new hope to patients!
**Study Highlights**
In this study, 18 patients with advanced Parkinson’s disease (disease duration over 5 years) received four intranasal neural stem cell transplants. The results were impressive:
**Significant Improvement in Parkinson’s Disease Rating Scale Scores**:
By the 6th month of treatment, the MDS-UPDRS score decreased by an average of 19.9 points, showing the most significant improvement (p<0.001).
**No Serious Adverse Reactions**:
Post-treatment, no serious adverse reactions related to neural stem cells were observed, and brain MRI scans showed no tumor formation.
**Limitations of Traditional Parkinson’s Disease Treatments**
Current drug and surgical treatments cannot increase the number of dopamine neurons, resulting in limited efficacy. The innovative approach of using neural stem cells aims to address this issue.
**Neural Stem Cells: A Regenerative Hope**
Parkinson’s disease involves the loss of dopamine neurons. Neural stem cells can replace these lost neurons, controlling the disease progression at its root. PUMCH’s novel method of intranasal administration of neural stem cells marks a significant milestone in Parkinson’s disease treatment.
**Future Prospects**
Phase 1 research indicates that intranasal neural stem cell transplantation for Parkinson’s disease is safe, feasible, and effective. We look forward to future studies bringing hope to more patients!
**Follow us for more cutting-edge medical updates!**
To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
ParkinsonsDisease NeuralStemCells MedicalBreakthrough PUMCH NewHopeForHealth StemCell
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/06/微信截图_20240606173158.jpg)
The Chinese medical team’s Revolutionary CAR-T Therapy: Long-lasting asthma relief with a single injection
### 🚀 The Chinese medical team’s Revolutionary CAR-T Therapy: Long-lasting asthma relief with a single injection.!
![asthma](https://www.medtourcn.com/wp-content/uploads/2024/06/微信截图_20240606173158.jpg)
asthma
📢 Exciting news from the world of medical science! The team led by Professor Peng Min at Tsinghua University has made a groundbreaking advancement in CAR-T cell therapy. Imagine a world where chronic diseases like allergic asthma can be managed with just a single injection. This could soon be a reality!
🌬 **Asthma: A Global Challenge**
Asthma is one of the most common respiratory diseases, affecting over 300 million people worldwide and causing approximately 250,000 deaths annually. Despite the availability of treatments, many patients require lifelong medication, which can be costly and burdensome.
💡 **The Breakthrough Study**
On May 27, 2024, the team published their findings in *Nature Immunology*. Their paper, titled *A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice*, introduces a novel CAR-T cell named 5TIF4. This engineered cell targets the factors that trigger allergic reactions. Remarkably, just one injection of 5TIF4 cells was enough to suppress signs and symptoms of allergic asthma in mice for an extended period.
🧬 **How Does It Work?**
Traditional therapies for chronic diseases often require repeated or lifelong administration. However, the 5TIF4 cells are designed to be long-lived and multifunctional. They can neutralize eosinophils (cells involved in allergic reactions) and block key pathways (IL-4 and IL-13 signaling) that drive asthma. This innovative approach not only targets the symptoms but also addresses the underlying causes of the disease.
🚧 **Challenges and Solutions**
While CAR-T therapy has revolutionized cancer treatment, applying it to non-cancerous diseases presents unique challenges:
-
**Targeting Non-Cancer Tissues**: Unlike tumors, affected organs like lungs in chronic diseases cannot be eliminated.
-
**Longevity of Therapy**: Chronic diseases are lifelong, necessitating long-lasting therapeutic cells.
-
**Safety**: Current CAR-T treatments often involve invasive procedures like chemotherapy, which are not suitable for chronic conditions.
Peng Min’s team overcame these hurdles by engineering CAR-T cells that do not require pre-treatment and can persist in the body, providing continuous protection against asthma.
💭 **Future Prospects**
The implications of this research are profound. If these results can be replicated in humans, we might see a new era where a single injection offers long-term relief from asthma. Moreover, the same principles could potentially be adapted to treat other diseases involving eosinophils and type 2 cytokines, such as allergies, atopic dermatitis, and eosinophilic esophagitis.
📰 *Nature Immunology* also highlighted this study in an article titled *CAR T cells put the brakes on asthma*, emphasizing the expanding scope of CAR-T therapy beyond cancer treatment.
🌟 **Conclusion**
This pioneering research by Tsinghua University marks a significant milestone in the fight against chronic diseases. With further clinical trials, we could be on the brink of a revolution in how we treat asthma and possibly other chronic conditions. Stay tuned for more updates on this exciting journey towards better health and wellness!
📸 Don’t forget to follow for more groundbreaking health news and updates!
🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
#MedicalBreakthrough #CARTCellTherapy #AsthmaRelief #TsinghuaUniversity #HealthRevolution
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/06/20240604.png)
Nature Medicine | New Hope! Chinese Medical Team Makes Breakthrough in Gastric Adenocarcinoma Treatment
Nature Medicine | **New Hope! Chinese Medical Team Makes Breakthrough in Gastric Adenocarcinoma Treatment**
![Nature Medicine](https://www.medtourcn.com/wp-content/uploads/2024/06/20240604.png)
Nature Medicine
In the medical field, unresectable advanced or metastatic gastric or gastroesophageal junction (#GEJ) adenocarcinoma has always been a daunting challenge. However, the latest research brings new hope to this field. #metastaticgastric #gastroesophagealjunction
**Innovative Treatment Brings New Hope**
**Key Findings**
**Dawning of Hope**
**Conclusion**
#GastricAdenocarcinomaTreatment #MedicalInnovation #HopeForHealth #gastriccarcinoma #gastriccancer #HER2 #Adenocarcinoma #cancertretment #chinesemedical #medicalscience #hope #hopeforhealth #NatureMedicine
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/05/微信截图_20240527172836.jpg)
New Breakthrough! Chinese Medical Team’s Remarkable Results with CLDN18.2 CAR-T Therapy for Pancreatic Cancer!
“New Breakthrough! Chinese Medical Team’s Remarkable Results with CLDN18.2 CAR-T Therapy for Pancreatic Cancer! 🎉”
![Pancreatic Cancer](https://www.medtourcn.com/wp-content/uploads/2024/05/微信截图_20240527172836.jpg)
Pancreatic Cancer
On May 25, 2024, the Journal of Clinical Oncology (JCO) published groundbreaking research by Professor Lin Shen’s team from Peking University Cancer Hospital on the application of CLDN18.2 CAR-T cell therapy for refractory metastatic pancreatic cancer, achieving impressive outcomes!
This study summarized the results of two phase I/Ib prospective clinical trials, involving a total of 24 advanced pancreatic cancer patients. Observations post-treatment revealed partial tumor shrinkage and significant reductions in CA19-9 levels in some patients, indicating a positive response. The research also demonstrated that CLDN18.2 CAR-T therapy not only showed significant efficacy in second- and third-line treatments but also exhibited promising potential in extending patient survival.
Assessment of treatment safety showed that the safety profile of CT041 cell therapy in this study was similar to previous findings, with no predefined dose-limiting toxicities observed. Treatment-related adverse events were mainly manageable, with cytokine release syndrome (CRS) and gastrointestinal adverse events typically mild and alleviated through proactive clinical management.
The results of this study demonstrate the potential and prospects of CLDN18.2 CAR-T cell therapy in CLDN18.2-positive metastatic pancreatic cancer patients. Significant reductions in CA19-9 levels, a disease control rate of 70.8%, and a significant extension of overall survival were observed, with treatment safety effectively controlled.
The publication of these research findings brings new hope for pancreatic cancer patients and provides important references for further research and clinical application of CLDN18.2 CAR-T cell therapy. We look forward to this breakthrough bringing gospel to more patients! 🌟
🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
#PancreaticCancer #CAR-TTherapy #MedicalBreakthrough
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/05/微信截图_20240510093433.jpg)
Historic Moment! Chinese Medical Team Successfully Cures Diabetes Patient
![🌟](https://static.xx.fbcdn.net/images/emoji.php/v9/te0/1/16/1f31f.png)
**Historic Moment! Chinese Medical Team Successfully Cures Diabetes Patient** ![✨](https://static.xx.fbcdn.net/images/emoji.php/v9/tf4/1/16/2728.png)
![🌟](https://static.xx.fbcdn.net/images/emoji.php/v9/te0/1/16/1f31f.png)
![Diabetes](https://www.medtourcn.com/wp-content/uploads/2024/05/微信截图_20240510093433.jpg)
Diabetes
![🎉](https://static.xx.fbcdn.net/images/emoji.php/v9/t8c/1/16/1f389.png)
![🎊](https://static.xx.fbcdn.net/images/emoji.php/v9/tb4/1/16/1f38a.png)
**Miracle of Health Restoration**
**Technological Redemption**
**A New Era of Regenerative Medicine**
**Future Prospects**
**The World Changes Because of China**
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/04/2024042200000.png)
AACR 2024/Breakthrough Chinese Research – Monotherapy for Late-stage #SolidTumors and #Lymphomas
AACR 2024/Breakthrough Chinese Research – Monotherapy for Late-stage #SolidTumors and #Lymphomas![🔥](https://static.xx.fbcdn.net/images/emoji.php/v9/ta9/1.5/16/1f525.png)
![AACR2024](https://www.medtourcn.com/wp-content/uploads/2024/04/2024042200000.png)
AACR2024
#AACR2024
![⭐️](https://static.xx.fbcdn.net/images/emoji.php/v9/t3b/1.5/16/2b50.png)
#TQB2916
![❄️](https://static.xx.fbcdn.net/images/emoji.php/v9/tb5/1.5/16/2744.png)
#CD40
![💦](https://static.xx.fbcdn.net/images/emoji.php/v9/t1a/1.5/16/1f4a6.png)
#ECOG
![☀️](https://static.xx.fbcdn.net/images/emoji.php/v9/tf4/1.5/16/2600.png)
#Realcase
![✨](https://static.xx.fbcdn.net/images/emoji.php/v9/t7b/1.5/16/2728.png)
#Lymphomas
![🌤](https://static.xx.fbcdn.net/images/emoji.php/v9/ta6/1.5/16/1f324.png)
#Conclusion
TQB2916 achieves CD40 engagement and immune activation through cytokine modulation. With its promising safety and efficacy profile, 200mg has been identified as the preliminary expansion dose. Studies exploring TQB2916 in combination with immune checkpoint inhibitors and/or other anti-cancer therapies are currently underway.
Stay tuned for more updates on this groundbreaking treatment!
![💥](https://static.xx.fbcdn.net/images/emoji.php/v9/t99/1.5/16/1f4a5.png)
doctor.huang@globecancer.com
WhatsApp +86137 1795 9070
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/04/微信截图_20240419175203.jpg)
AACR 2024/Breakthrough in Treating Recurrent or Metastatic Nasopharyngeal Carcinoma by Chinese Medical Team
AACR 2024/Breakthrough in Treating Recurrent or Metastatic Nasopharyngeal Carcinoma by
Chinese Medical Team![🇨🇳](https://static.xx.fbcdn.net/images/emoji.php/v9/t5f/1.5/16/1f1e8_1f1f3.png)
![AACR 2024](https://www.medtourcn.com/wp-content/uploads/2024/04/微信截图_20240419175203.jpg)
AACR 2024
We’re thrilled to share groundbreaking updates from the 2024 American Association for Cancer Research (AACR) Annual Meeting!
China’s innovative pharmaceuticals are making waves in early clinical trials, hinting at promising breakthroughs in cancer treatment!
At the forefront is the remarkable research on Treprilimumab, a monoclonal antibody, showcased by Prof. Ma Haiqiang and his team from Sun Yat-sen University Cancer Center.
Their pioneering work focuses on advancing treatments for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), a challenging form of cancer.
Treprilimumab, administered subcutaneously, has shown remarkable safety and preliminary efficacy when combined with Gemcitabine and Cisplatin (GP), earning FDA approval in October 2023 for first-line therapy in RM-NPC.
The team initiated the first human clinical trial to assess Treprilimumab’s pharmacokinetics in RM-NPC, aiming to establish optimal subcutaneous dosing regimens for future trials.
The study enrolled RM-NPC patients, confirmed histologically, and previously untreated systemically. Patients received Treprilimumab SC at 240mg Q3W, 360mg Q3W, or 480mg Q6W, in combination with GP for up to 6 cycles, followed by Treprilimumab SC monotherapy until disease progression, intolerable toxicity, or completion of 2 years of treatment. Tumor response was assessed by RECISTv1.1 criteria, with primary endpoints focusing on pharmacokinetics and secondary endpoints including safety, efficacy, and immunogenicity.
From November 24, 2022, to November 20, 2023, 38 patients were enrolled, with a median follow-up of 6.8 months. The median age was 49, with 73.7% male. Pharmacokinetic analysis revealed comparable exposure between Treprilimumab 360mg Q3W SC and 240mg Q3W IV in the first cycle. Overall response rates (ORR) were 100%, 92.3%, and 92.3% for the 240mg, 360mg, and 480mg groups, respectively. By November 20, 2023, 71.1% of patients experienced sustained remission, with no new safety concerns. Grade ≥3 adverse events (AEs) occurred in 76.3% of patients, with no fatalities. Immune-related AEs were reported in 36.8% of patients, with one case of grade ≥3.
These groundbreaking findings demonstrate comparable safety and clinical efficacy between Treprilimumab SC and IV formulations when combined with GP in treating RM-NPC patients. The exposure of Treprilimumab 360mg Q3W SC mirrors that of 240mg Q3W IV. Excitingly, Treprilimumab SC formulations are slated for Phase III clinical development, promising hope for enhanced cancer therapies!
Stay tuned for more updates on this game-changing research!
To assess whether the condition is suitable for Chinese Top level therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: 137 1795 9070
Email: doctor.huang@globecancer.com
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/04/20240401000000.jpg)
🎉💉 Exciting Breakthrough Alert! Chinese Medical Team Unveils Game-Changing mRNA Cancer Vaccine 🎉💉
🎉💉 Exciting Breakthrough Alert! Chinese Medical Team Unveils Game-Changing mRNA Cancer Vaccine 🎉💉
![Advanced Science](https://www.medtourcn.com/wp-content/uploads/2024/04/20240401000000.jpg)
Advanced Science
Say hello to the future of cancer treatment! A groundbreaking mRNA cancer vaccine jointly developed by Chinese scientists has hit the spotlight, promising to elevate tumor suppression rates and extend survival periods.
🔬 What’s the Buzz? 🔬
Published in the prestigious journal “Advanced Science”, the research titled “All-Trans-Retinoic Acid-Adjuvanted mRNA Vaccine Induces Mucosal Anti-Tumor Immune Responses for Treating Colorectal Cancer” reveals a novel mRNA cancer vaccine. This vaccine, packaged with lipid nanoparticles (LNPs), delivers All-Trans-Retinoic Acid (ATRA) and mRNA, effectively stimulating mucosal immune responses in the intestines. Compared to conventional mRNA-LNP vaccines, this innovative approach significantly boosts tumor suppression and prolongs survival rates.
🩺 Why It Matters 🩺
Colorectal cancer ranks third in cancer incidence and second in mortality globally. Conventional treatments such as surgery, chemotherapy, and radiation often come with high recurrence rates. Enter cancer immunotherapy—the beacon of hope in the fight against colorectal cancer. Cancer vaccines, a vital component of immunotherapy, harness the body’s immune system to target and destroy cancer cells. With the recent success of mRNA vaccines for COVID-19, mRNA cancer vaccines have garnered immense attention for their potential to revolutionize cancer treatment.
🚀 The Breakthrough 🚀
The key lies in ATRA-LNP’s ability to induce cytotoxic T cells in the intestines, offering a promising therapeutic approach for colorectal cancer. In animal models, ATRA-LNP treatment led to a remarkable reduction in tumor growth and extended survival rates compared to conventional treatments. These findings underscore the potential of mRNA cancer vaccines, particularly in enhancing the treatment outcomes for colorectal cancer patients.
🌟 The Takeaway 🌟
With its ability to activate anti-tumor immune responses at mucosal surfaces, the novel mRNA cancer vaccine brings hope for improved outcomes in colorectal cancer treatment. ATRA incorporation into LNPs not only enhances mRNA delivery efficiency but also directs activated T cells towards the intestines, amplifying their anti-tumor effects. This study paves the way for a promising future in enhancing the efficacy of mRNA cancer vaccines against colorectal cancer.
🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
Email: doctor.huang@globecancer.com,
WhatsApp: 137 1795 9070
#CancerResearch #MedicalBreakthrough #ImmunotherapyInAction #ColorectalCancerFighters #mRNA #CancerVaccine #vaccine #colorectal #colorectalcancer #cancerfighters #chinesemedical #cancertreatment #tumor
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/03/202403190000.jpg)
Another BCMA CAR-T therapy for multiple myeloma hits the market in China! – 🔥Long-term efficacy 🔥
🌎Another BCMA CAR-T therapy for multiple myeloma hits the market in China!
– 🔥Long-term efficacy 🔥
![multiple myeloma](https://www.medtourcn.com/wp-content/uploads/2024/03/202403190000.jpg)
multiple myeloma
🌙China has made significant breakthroughs in the treatment of multiple myeloma with BCMA CAR-T therapy, attracting global attention. Recently, two fully human BCMA CAR-T therapies, Equecabtagene Autoleucel and Zevorcabtagene Autoleucel, have been approved for the treatment of relapsed/refractory multiple myeloma.⭐️
🌛 In terms of long-term efficacy, for patients with a CAR-T cell persistence of over one year, the percentage is 53.3% for Equecabtagene Autoleucel and 26.5% for Zevorcabtagene Autoleucel at six months’ persistence.⭐️
🌜The duration of CAR-T cell persistence has an impact on the survival outcome of multiple myeloma (MM) patients. Long-term follow-up data from the Lengend-2 study showed a significant improvement in the cumulative overall survival (OS) rate for RRMM patients with a CAR-T cell persistence of over 280 days compared to patients with a persistence of less than 280 days. Therefore, 280 days of persistence is a critical threshold for improving clinical outcomes.⭐️
✨The median persistence for Zevorcabtagene Autoleucel is 77 days, while for Equecabtagene Autoleucel, it is 419 days, far exceeding the critical threshold. It is expected to improve the OS of MM patients.⭐️
🌤From a clinical perspective, both therapies demonstrate a trend of improving long-term efficacy over time.
The complete response (CR) rate at six months of follow-up is 54.8% for Equecabtagene Autoleucel and 35.0% for Zevorcabtagene Autoleucel.⭐️
🌝At a median follow-up of around nine months, the registered clinical data from China shows a CR rate of ≥74.2% for Equecabtagene Autoleucel and 45.1% for Zevorcabtagene Autoleucel.⭐️
🌞During the 2023 IMS conference, Equecabtagene Autoleucel presented the latest long-term follow-up data, revealing a further increase in the CR rate to 82.4% at a median follow-up of 18.07 months.⭐️
☀️The efficacy data following a median follow-up of nine months for Zevorcabtagene Autoleucel in the registered clinical trial LUMMICAR-1 Phase 2 study has not been publicly disclosed.
China’s breakthroughs in CAR-T cell therapy are remarkable. It not only provides new treatment options for multiple myeloma patients but also demonstrates China’s strength in medical research and innovation. It brings hope and possibilities for improving patients’ survival and quality of life.⭐️
🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: 137 1795 9070
Email: doctor.huang@globecancer.com
#BCMACART #MultipleMyeloma #Innovation #CART #CARTTherapy #chinesemedical
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/03/2024031800000.jpg)
Another BCMA CAR-T therapy for multiple myeloma hits the market in China! – Short-term efficacy
Another BCMA CAR-T therapy for multiple myeloma hits the market in China!
– Short-term efficacy ![✨](https://static.xx.fbcdn.net/images/emoji.php/v9/t7b/1.5/16/2728.png)
![multiple myeloma](https://www.medtourcn.com/wp-content/uploads/2024/03/2024031800000.jpg)
multiple myeloma
China CAR-T therapy
![🌟](https://static.xx.fbcdn.net/images/emoji.php/v9/t39/1.5/16/1f31f.png)
In the field of multiple myeloma (MM),
![💉](https://static.xx.fbcdn.net/images/emoji.php/v9/t26/1.5/16/1f489.png)
BCMA
![🎯](https://static.xx.fbcdn.net/images/emoji.php/v9/t9/1.5/16/1f3af.png)
Looking at the short-term efficacy
![💥](https://static.xx.fbcdn.net/images/emoji.php/v9/t99/1.5/16/1f4a5.png)
![📆](https://static.xx.fbcdn.net/images/emoji.php/v9/t58/1.5/16/1f4c6.png)
![📊](https://static.xx.fbcdn.net/images/emoji.php/v9/t3/1.5/16/1f4ca.png)
![💉](https://static.xx.fbcdn.net/images/emoji.php/v9/t26/1.5/16/1f489.png)
![⚖️](https://static.xx.fbcdn.net/images/emoji.php/v9/t91/1.5/16/2696.png)
![🌈](https://static.xx.fbcdn.net/images/emoji.php/v9/t6c/1.5/16/1f308.png)
![🔬](https://static.xx.fbcdn.net/images/emoji.php/v9/td7/1.5/16/1f52c.png)
![🎉](https://static.xx.fbcdn.net/images/emoji.php/v9/te5/1.5/16/1f389.png)
![🎉](https://static.xx.fbcdn.net/images/emoji.php/v9/te5/1.5/16/1f389.png)
WhatsApp: 137 1795 9070
Email: doctor.huang@globecancer.com
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/01/202401110.jpg)
Breakthrough CAR-T Cell Therapy for R/R B-Cell ALL: A Game-Changer in Chinese Medical Innovation
![](https://www.medtourcn.com/wp-content/uploads/2024/01/202401110.jpg)
![](https://www.medtourcn.com/wp-content/uploads/2024/01/202401112.jpg)